WO1993009233A3 - Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states - Google Patents

Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states Download PDF

Info

Publication number
WO1993009233A3
WO1993009233A3 PCT/US1992/009400 US9209400W WO9309233A3 WO 1993009233 A3 WO1993009233 A3 WO 1993009233A3 US 9209400 W US9209400 W US 9209400W WO 9309233 A3 WO9309233 A3 WO 9309233A3
Authority
WO
WIPO (PCT)
Prior art keywords
kpi
peptide
treatment
disease states
precursor protein
Prior art date
Application number
PCT/US1992/009400
Other languages
French (fr)
Other versions
WO1993009233A2 (en
Inventor
Steven L Wagner
Robert Siegel
Gregory P Thill
Michael M Harpold
William T Comer
Original Assignee
Salk Inst Biotech Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst Biotech Ind filed Critical Salk Inst Biotech Ind
Publication of WO1993009233A2 publication Critical patent/WO1993009233A2/en
Publication of WO1993009233A3 publication Critical patent/WO1993009233A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to the production of a Kuniz type protease inhibitor (KPI) peptide, and its use in regulating protease activity associated with amyloidosis. This invention is further directed to in vivo and in vitro models of amyloidosis involving the KPI peptide. The KPI peptide can also be used to treat coagulation disorders by regulating proteases in the coagulation pathway. KPI is also used to inhibit or ameliorate protease-associated damage following injury, especially head injury. Nucleic acid sequences encoding the protease inhibitor and expression systems for high level expression of the active inhibitor are provided.
PCT/US1992/009400 1991-10-31 1992-10-30 Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states WO1993009233A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78563891A 1991-10-31 1991-10-31
US785,638 1991-10-31

Publications (2)

Publication Number Publication Date
WO1993009233A2 WO1993009233A2 (en) 1993-05-13
WO1993009233A3 true WO1993009233A3 (en) 1993-08-05

Family

ID=25136137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/009400 WO1993009233A2 (en) 1991-10-31 1992-10-30 Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states

Country Status (2)

Country Link
AU (1) AU3061092A (en)
WO (1) WO1993009233A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
ATE220105T1 (en) * 1991-04-01 2002-07-15 Merck & Co Inc GENES AFFECTING THE PROTEOLYTIC ACTIVITY OF PICHIA AND THEIR USE
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
JP3626982B2 (en) * 1997-08-29 2005-03-09 アークレイ株式会社 Method for measuring proteolytic enzyme inhibitor and measurement kit used therefor
AU4229599A (en) * 1998-06-03 1999-12-20 Scios Inc. Protease inhibitor peptides
US7015317B2 (en) 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DK1941867T3 (en) 2002-06-07 2012-01-02 Dyax Corp Polypeptide with Modified Kunitz Domain
SI2386310T1 (en) 2002-08-28 2019-03-29 Dyax Corp. Methods for preserving organs and tissues
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CA3168591A1 (en) 2010-01-06 2011-07-14 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
KR102502293B1 (en) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 Plasma kallikrein binding proteins
NZ744233A (en) 2015-12-11 2023-11-24 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393431A1 (en) * 1989-04-18 1990-10-24 Bayer Ag Homologues of Alzheimer protease inhibitor prepared genetechnologically, host-strains and expression vectors for their preparation and use as a medicament
WO1990014840A1 (en) * 1989-06-06 1990-12-13 California Biotechnology Inc. Recombinant alzheimer's amyloid protein
WO1990014841A1 (en) * 1989-06-06 1990-12-13 California Biotechnology Inc. Pharmaceutical compositions and methods of treatment using alzheimer's amyloid polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0393431A1 (en) * 1989-04-18 1990-10-24 Bayer Ag Homologues of Alzheimer protease inhibitor prepared genetechnologically, host-strains and expression vectors for their preparation and use as a medicament
WO1990014840A1 (en) * 1989-06-06 1990-12-13 California Biotechnology Inc. Recombinant alzheimer's amyloid protein
WO1990014841A1 (en) * 1989-06-06 1990-12-13 California Biotechnology Inc. Pharmaceutical compositions and methods of treatment using alzheimer's amyloid polypeptides

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANN. REV. BIOCHEM. vol. 49, 1980, PALO ALTO, CA, US pages 593 - 626 M. LASKOWSKI, JR. ET I. KATO 'PROTEIN INHIBITORS OF PROTEINASES' *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 186, no. 2, 31 July 1992, DULUTH, MINNESOTA US pages 1138 - 1145 S.L. WAGNER ET AL. 'high level expression, purification, and characterization of the kunitz-type protease inhibitor domain of protease nexin-2/amyloid beta-protein precursor' *
BIOL. CHEM. HOPPE-SEYLER, VOL. 369 SUPPL. May 1988, BERLIN, FRG pages 149 - 152 M. LARVIN ET AL. 'Intra-Peritoneal Aprotinin Therapy for Acute Pancreatitis' *
FEBS LETTERS vol. 267, no. 2, July 1990, AMSTERDAM NL pages 207 - 212 M. CASTRO ET AL. 'Does the Kunitz domain from the Alzheimer's amyloid beta protein precursor inhibit a kallikrein responsible for post-translational processing of nerve growth factor precursor' *
J. IND. MICROBIOL. vol. 7, no. 3, April 1991, pages 197 - 202 T. VEDVICK ET AL. 'HIGH-LEVEL SECRETION OF BIOLOGICALLY ACTIVE APROTININ FROM THE YEAST PICHIA-PASTORIS' *
JOURNAL OF BIOLOGICAL CHEMISTRY. (MICROFILMS) vol. 265, no. 17, 15 June 1990, BALTIMORE, MD US pages 9591 - 9594 W.E. VAN NOSTRAND ET AL. 'Immunopurification and Protease Inhibitory Properties of Protease Nexin-2/Amyloid beta-Protein Precursor' cited in the application *
NEUROCHEMICAL RESEARCH vol. 14, no. 10, 1989, NEW YORK, US G.M. COLE ET AL. 'Evidence for Lysosomal Processing of Amyloid beta-Protein Precursor in Cultured Cells' *

Also Published As

Publication number Publication date
WO1993009233A2 (en) 1993-05-13
AU3061092A (en) 1993-06-07

Similar Documents

Publication Publication Date Title
WO1993009233A3 (en) Recombinant amyloid precursor protein inhibitor domain and treatment of various disease states
ATE281470T1 (en) RECOMBINANT PROTEASE INHIBITOR OF ALZHEIMER AMYLOID PROTEIN
IL77781A (en) Cdna,vectors and methods for expression of human protein c activity
WO2001083782A3 (en) Novel proteases
EG20273A (en) Process for preparing of pyrazolopyrimidines and their use in the treatment of stress related and other diseases
ATE149833T1 (en) USE OF AMINO-2-TRIFLUOROMETHOXY-6-BENZOTHIAZOLE (RILUZOLE) FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF MOTONEURON DISEASES
WO2002045749A3 (en) Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
HUP0400988A2 (en) Use of compounds with combined nep/mp-inhibitory activity in the preparation of medicaments
ES2096577T3 (en) USE OF CETOCONAZOLE AND A RETINOID FOR THE TREATMENT OF VULGAR ACNE.
WO2002002133A3 (en) Peptide composition for treatment of periodontal diseases and prevention of skin aging
WO1996034890A3 (en) Inhibitors of fibrin cross-linking and/or transglutaminases
GB9925005D0 (en) The treatment of wounds
DE69423577T2 (en) Use of oenothein B in the manufacture of a medicament for the treatment of disorders caused by hyperandrogenicity.
NO20053237L (en) Azapeptide.
ATE534399T1 (en) USE OF HYALURONIDASE FOR PROPHYLAXIS AND TREATMENT OF CARDIOVASCULAR DISEASES
WO2003004046A3 (en) Use of xaa-pro peptidases for the treatment of substance p-related disorders
FR2694694B1 (en) Active composition for the treatment of psoriasis, in particular psoriasis of the scalp.
DE69113049T2 (en) VARIANTS OF THE TISSUE PLASMINOGEN ACTIVATOR WITH REDUCED DISASSEMBLY.
EP1103272A2 (en) Modulation of TGF-beta by proteolytic enzymes
WO2004026331A8 (en) Peptides inhibiting specific cleaving activities of presenilins
KR200193398Y1 (en) Dermatophytosis spray
ATE452139T1 (en) PEPTIDE BAIT FOR THE PRODUCTION OF MEDICATIONS USED FOR THE PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES OR PROBLEMS ASSOCIATED WITH THE APPEARANCE OF ANTIBODIES DIRECTED TO EXOGENE PROTEINS
TR199900040T2 (en) Method for the treatment and prevention of neurodegenerative diseases by administering a thiazolidinone.
DE69105213T2 (en) SUBSTITUTION VARIANT OF THE TISSUE PLASMINOGEN ACTIVATOR.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KR LK MG MN MW NO PL RO RU SD US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 240670

Date of ref document: 19940922

Kind code of ref document: A

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA